加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.87
−US$0.0107 · -1.21%
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
前收盘价
US$0.87
−US$0.0107 · -1.21%
盘前
US$0.891
+US$0.021 · +2.41%
10月12日 8:55 ET
盘中时间采用ET。市场数据可能有所延迟。
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
日内区间
当前US$0.87
52周区间
当前US$0.87
盘中时间采用ET。市场数据可能有所延迟。
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
日内区间
当前US$0.87
52周区间
当前US$0.87
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.4万 USD | 2603.3万 USD | — | — | — |
| 毛利 | 6.4万 USD | 2603.3万 USD | — | — | — |
| 研究与开发 | 3779.8万 USD | 2925.6万 USD | 5300.2万 USD | 9663万 USD | 8049.6万 USD |
| 销售、一般及管理费用 | 2034万 USD | 1922.9万 USD | 1605.4万 USD | 2080.6万 USD | 1901.4万 USD |
| 营业费用 | 5813.8万 USD | 4848.5万 USD | 6905.6万 USD | 1.19亿 USD | 9810.7万 USD |
| 利息收入 | 226.8万 USD | 445.3万 USD | 5199 USD | 156.5万 USD | 9.77万 USD |
| 利息支出 | — | — | — | 2.1万 USD | 6909.14 USD |
| 折旧和摊销 | 70.4万 USD | 66万 USD | 72万 USD | 103.1万 USD | 63.4万 USD |
| 营业利润 | −5807.4万 USD | −2245.2万 USD | −6905.6万 USD | −1.19亿 USD | −9810.7万 USD |
| 净利润 | −5548万 USD | −1562.8万 USD | −6210.6万 USD | −1.18亿 USD | −2.02亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.60
上涨空间 658.62%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM34.54万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO19.35万0.00%180亿 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO10万0.00%139.17亿 USD0.24%US$356.78+0.94%
iShares Micro-Cap ETFIWC4.18万0.00%13.17亿 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG2.17万0.00%17亿 USD0.06%US$260.49+0.91%
Vanguard Russell 2000 Value ETFVTWV1.45万0.00%14亿 USD0.06%US$185.81-0.13%
iShares Russell 2500 ETFSMMD7255.290.00%40.62亿 USD0.23%US$86.29+0.38%
Global X - Russell 2000 ETFRSSL6265.74—14.19亿 USD0.08%US$109.09+0.21%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGVanguard Russell 2000 Value ETFVTWViShares Russell 2500 ETFSMMDGlobal X - Russell 2000 ETFRSSLAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
